Research Funding

LB506 Cancer & Smoking Disease Research Program Now Accepting Applications

The application period is between November 23, 2015 and January 25, 2016.

The Nebraska Department of Health & Human Services, Cancer and Smoking Disease Research Program is now accepting applications for Fiscal Year 2017 Cancer and Smoking Disease Research Grants.

The Nebraska Cancer and Smoking Disease Research Program was created by the Nebraska Legislature in 1981, when one-cent (1¢) of the tax per pack of cigarettes sold in the state was designated to fund the program.

A portion of the revenue generated from the tax also funds the University of Nebraska Eppley Institute for Research in Cancer and Allied Diseases and the Cancer Registry at the Nebraska Department of Health & Human Services. The remainder is awarded to all campuses of the University of Nebraska and Creighton University which compete annually for the funds. Click here for a listing of the currently awarded grants.

In 1993, the Nebraska Legislature increased the tobacco excise tax on cigarettes and appropriated an additional two cents (2¢) per pack for cancer and smoking disease research. The revenue from the two-cent program is distributed to the University of Nebraska Eppley Institute for Research in Cancer and Allied Diseases, and other postsecondary educational institutions having colleges of medicine located in Nebraska which have cancer research programs (Creighton University). The primary purpose of the program is to build research capacity


In order to be considered for funding, applications must be received by 5:00 p.m. Monday, January 25, 2016 – NO EXCEPTIONS.

Any questions can be sent to

Download the application instructions 2016-17_CSDR_506Instructions  or from the Nebraska Department of Health and Human Services website




The U. S. Department of Energy’s Experimental Program to Stimulate Competitive Research (DOE EPSCoR) hereby announces its interest in receiving applications for building EPSCoR-State/DOE-National Laboratory Partnerships. These partnerships are to advance fundamental energy oriented scientific and engineering research collaborations with the DOE Federally Funded Research and Development Centers (DOE FFRDCs hereafter referred to as the National Laboratories) (Information on the DOE National Laboratories can be found at ). Participation by graduate students and/or postdoctoral fellows is required. Junior faculty from EPSCoR jurisdictions are encouraged to apply. Utilization of DOE user facilities is encouraged. (Information on the DOE Office of Science user facilities can be found at , information on the DOE Office of Nuclear Energy user facilities can be found at )

Biological and Environmental Research (BER) Area:

BER advances world-class biological and environmental research programs and scientific user facilities to support DOE’s energy, environment, and basic research missions.

The Biological and Environmental Research (BER) program supports fundamental research and scientific user facilities to address diverse and critical global challenges. The program seeks to understand how genomic information is translated to functional capabilities, enabling more confident redesign of microbes and plants for sustainable biofuel production, improved carbon storage, or contaminant bioremediation. BER research advances understanding of the roles of Earth’s biogeochemical systems (the atmosphere, land, oceans, sea ice, and subsurface) in determining climate so we can predict climate decades or centuries into the future, information needed to plan for future energy and resource needs. Solutions to these challenges are driven by a foundation of scientific knowledge and inquiry in atmospheric chemistry and physics, ecology, biology, and biogeochemistry.

General inquiries about this FOA should be directed to the Technical/Scientific Program Contact:

Dr. Tim Fitzsimmons


DOE EPSCoR Partner FOA_Notice


FY15 Extremity Regeneration Intervention


Pre-Application Deadline: 5:00 p.m. Eastern time (ET), December 15, 2015

Application Submission Deadline: 11:59 p.m. ET, December 22, 2015

Independent extramural investigators at all academic levels (or equivalent)

·         Supports Phase I, II, or pivotal clinical trial phase development projects focused on extremity regeneration.

·         The focus is on bone and soft tissue reconstruction, limb and tissue salvage technologies, and

·         regenerative medicine technologies for the treatment of trauma-induced damage.

·         Must specifically address one or both of the FY15 Focus Areas.

·         Funding from this award mechanism must support a clinical trial and development-related efforts and

·         may not be used for preclinical research studies.

·         The maximum period of performance is 4 years.

·         The maximum allowable funding (total costs) for the entire period of performance is $4.9 Million.


A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the website.  The application package containing the required forms for each award mechanism can also be found on  A listing of all CDMRP funding opportunities can be obtained on the website by performing a basic search using CFDA Number 12.420.


Applications must be submitted through the federal government’s single-entry portal,  Requests for email notification of the Program Announcements release may be sent to  For more information about the PRORP or other CDMRP-administered programs, please visit the CDMRP website (

The JPC-8/CRMRP is one of six major DHP core research program areas within the DHP DHA RDA Directorate and is administered with oversight from JPC-8, which consists of Department of Defense (DoD) and non-DoD medical and military technical experts relevant to the program area. The JPC-8/CRMRP focuses on innovations to reconstruct, rehabilitate, and provide definitive care for injured Service members. The ultimate goal is to return the Service members to duty and restore their quality of life. Innovations developed from JPC-8/CRMRP-supported research efforts are expected to improve restorative treatments and rehabilitative care to maximize function for return to duty (RTD) or civilian life. The interest is in medical technologies (drugs, biologics, and devices) and treatment/rehabilitation strategies (methods, guidelines, standards, and information) that will significantly improve the medical care provided to our wounded Service members within the DoD health care system. Implementation of these technologies and strategies should improve the rate of RTD of Service members, the time to RTD, clinical outcome measures, and quality of life, as well as reduce the hospital stay lengths, clinical workload (patient encounters, treatments, etc.), and initial and long-term costs associated with restorative and rehabilitative or acute care.

Point of Contact:

CDMRP Help Desk 301-682-5507